XC130 / Xoc Pharma - LARVOL DELTA

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=56; Active, not recruiting; Sponsor: Xoc Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=40 ➔ 56; Trial completion date: Jan 2020 ➔ Apr 2022; Trial primary completion date: Jan 2020 ➔ Jan 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

[VIRTUAL] Assessment of a Novel Long Lasting Dopamine Agonist in the Unilateral 6-OHDA Lesion Model of Parkinson’s Disease (AAN 2021) - "The evaluation of XC130-A10H in the unilateral 6-OHDA model strongly suggests that XC130-A10H could be an important novel addition to therapy throughout the time course of Parkinson’s disease."

CNS Disorders • Parkinson's Disease

[VIRTUAL] In Vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety (AAN 2021) - "Key in vitro safety and efficacy indicators are assessed and contrasted with the reference dopamine agonist compounds, lisuride and pergolide. The in vitro receptor activity profile shows that XC130-A10H could represent an important addition to the therapeutic armamentarium throughout the time course of Parkinson’s disease."

Preclinical • CNS Disorders • Parkinson's Disease • Psychiatry

[VIRTUAL] Interim Results of a Phase 1 Single Ascending Dose Study of XC101-D13H, a Novel Compound for the Prevention of Migraine (AHS 2020) - "In the early cohorts of this Phase 1 study, XC130-D13H was well tolerated and showed suitable pharmacokinetics for daily oral dosing. The receptor profile and initial clinical results support the prospect that XC101-D13H can prevent migraine without inducing the most important serotonergic agonist-driven side effects."

P1 data • CNS Disorders • Migraine • Pain

In-vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety (AAN 2020) - "Key in-vitro safety and efficacy indicators are assessed and contrasted with the reference dopamine agonist compounds, lisuride and pergolide... The in-vitro receptor activity profile suggests that XC130-A10H could represent an important addition to the therapeutic armamentarium throughout the time course of Parkinson’s disease."

Newly added product (clinicaltrials.gov) - P1, Parkinson's Disease

Pipeline update